2023
Impact of Prophylactic Antibacterials on Coagulation Profiles and Bleeding in Patients with Acute Myeloid Leukemia/Myelodysplastic Syndrome
Allen C, Gautam S, Cheng W, Pine A, Podoltsev N, Zeidan A, Lee A, Shallis R. Impact of Prophylactic Antibacterials on Coagulation Profiles and Bleeding in Patients with Acute Myeloid Leukemia/Myelodysplastic Syndrome. Acta Haematologica 2023, 146: 287-292. PMID: 37166332, DOI: 10.1159/000530153.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultHumansLeukemia, Myeloid, AcuteMyelodysplastic SyndromesRetrospective StudiesConceptsAML/myelodysplastic syndromeAcute myeloid leukemiaInternational normalized ratioAntibacterial prophylaxisMyelodysplastic syndromeProphylactic antibacterialsCoagulation profileAcute myeloid leukemia/myelodysplastic syndromeDiagnosis of AMLHigher international normalized ratioLeukemia/myelodysplastic syndromePartial thromboplastin time prolongationYale-New Haven HospitalYale-New HavenRetrospective cohort studyAbnormal coagulation profileGroup of patientsTime of admissionHigh rateIndividual patient encountersInstitutional review boardAntibacterial exposureRelevant bleedingAdult patientsCohort study
2022
Association of iron infusion reactions with ABO blood type
Butt A, Muradashvili T, Soliman S, Li F, Burns AJ, Brooks A, Browning S, Bar N, Borgman G, Goshua G, Hwa J, Martin K, Rinder H, Tormey C, Pine AB, Bona RD, Lee AI, Neparidze N. Association of iron infusion reactions with ABO blood type. European Journal Of Haematology 2022, 109: 519-525. PMID: 35871468, DOI: 10.1111/ejh.13838.Peer-Reviewed Original ResearchMeSH KeywordsAnemia, Iron-DeficiencyDextransFerric Oxide, SaccharatedFerrosoferric OxideHumansIronProspective StudiesRetrospective StudiesConceptsGreater oddsBlood typeYale Cancer CenterInfusion-related reactionsRetrospective chart reviewLarger patient numbersABO blood typeType AB bloodChart reviewInfusion reactionsMost patientsHematology clinicIron sucroseMultivariable analysisProspective studyCancer CenterPatient numbersIron dextranRisk factorsIron infusionIron repletionPatientsPossible associationAB bloodBlood
2021
Liver injury in COVID-19 and IL-6 trans-signaling-induced endotheliopathy
McConnell MJ, Kawaguchi N, Kondo R, Sonzogni A, Licini L, Valle C, Bonaffini PA, Sironi S, Alessio MG, Previtali G, Seghezzi M, Zhang X, Lee A, Pine AB, Chun HJ, Zhang X, Fernandez-Hernando C, Qing H, Wang A, Price C, Sun Z, Utsumi T, Hwa J, Strazzabosco M, Iwakiri Y. Liver injury in COVID-19 and IL-6 trans-signaling-induced endotheliopathy. Journal Of Hepatology 2021, 75: 647-658. PMID: 33991637, PMCID: PMC8285256, DOI: 10.1016/j.jhep.2021.04.050.Peer-Reviewed Original ResearchConceptsLiver sinusoidal endothelial cellsLiver injuryInterleukin-6Sinusoidal endothelial cellsAlanine aminotransferaseLiver histologyD-dimerCOVID-19Primary human liver sinusoidal endothelial cellsSARS-CoV-2 infectionHuman liver sinusoidal endothelial cellsEndothelial cellsSoluble glycoprotein 130IL-6 levelsSmall-interfering RNA knockdownJAK inhibitor ruxolitinibFactor VIII activityProinflammatory factorsInflammatory signalsLarge cohortInhibitor ruxolitinibVWF antigenEndotheliopathyPatientsInjuryIntermediate‐dose anticoagulation, aspirin, and in‐hospital mortality in COVID‐19: A propensity score‐matched analysis
Meizlish ML, Goshua G, Liu Y, Fine R, Amin K, Chang E, DeFilippo N, Keating C, Liu Y, Mankbadi M, McManus D, Wang SY, Price C, Bona RD, Chaar C, Chun HJ, Pine AB, Rinder HM, Siner JM, Neuberg DS, Owusu KA, Lee AI. Intermediate‐dose anticoagulation, aspirin, and in‐hospital mortality in COVID‐19: A propensity score‐matched analysis. American Journal Of Hematology 2021, 96: 471-479. PMID: 33476420, PMCID: PMC8013588, DOI: 10.1002/ajh.26102.Peer-Reviewed Original ResearchConceptsProphylactic-dose anticoagulationAntiplatelet therapyHospital deathCumulative incidenceMultivariable regression modelsHospital mortalityHospitalized adult COVID-19 patientsAdult COVID-19 patientsPropensity score-matched patientsPropensity score-matched analysisCOVID-19Intensive antithrombotic therapyIntermediate-dose anticoagulationCohort of patientsCOVID-19 patientsPatient-specific covariatesAnticoagulation cohortAspirin cohortDose anticoagulationAntithrombotic therapyThrombotic complicationsHospitalized patientsPrimary outcomeIllness severityRegression models
2018
Wide Range of Clinical Outcomes in Patients with Gliomatosis Cerebri Growth Pattern: A Clinical, Radiographic, and Histopathologic Study
Ly KI, Oakley DH, Pine AB, Frosch MP, Chiou SH, Betensky RA, Pomerantz SR, Hochberg FH, Batchelor TT, Cahill DP, Dietrich J. Wide Range of Clinical Outcomes in Patients with Gliomatosis Cerebri Growth Pattern: A Clinical, Radiographic, and Histopathologic Study. The Oncologist 2018, 24: 402-413. PMID: 30097523, PMCID: PMC6519760, DOI: 10.1634/theoncologist.2018-0086.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedAged, 80 and overChildChild, PreschoolFemaleHumansMaleMiddle AgedNeoplasms, NeuroepithelialRetrospective StudiesYoung AdultConceptsGliomatosis cerebri growth patternClinical outcomesOverall survivalGC patientsMagnetic resonance imagingRadiographic involvementRadiographic criteriaMutation statusWorld Health Organization classificationCentral nervous system tumorsFavorable survival timeImproved overall survivalGrade 3 tumorsStandardized treatment approachWorse overall survivalGrade 2 tumorsImproved clinical outcomesNervous system tumorsPrognosticate patientsBrain involvementBrainstem involvementRadiographic extentHistopathologic featuresPoor prognosisHistopathologic study